

Data Sharing Statement

Article Info	https://dx.doi.org/10.21037/hbsn-23-134	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The survival data in particular will be shared, and we also found a correlation between the disease status with PFS, which has seldom been provided in previous studies.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	One years within the publication date, since the technique or survival date may be updated over time.
7	To whom will you share the data?	Medical oncologists and liver surgeons who are interested in studies of combination therapy of immunotherapy and radiotherapy.
8	For what type of analysis or purpose?	For analysis to evaluate the efficacy and safety of subsequent radiotherapy in liver cancer patients treated with immunotherapy.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: zhaoh@pumch.cn
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.